Cyclerion Therapeutics, Inc.
CYCN
$2.47
-$0.08-3.14%
| Weiss Ratings | CYCN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | CYCN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CYCN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.51 | |||
| Price History | CYCN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -6.08% | |||
| 30-Day Total Return | 4.22% | |||
| 60-Day Total Return | -30.81% | |||
| 90-Day Total Return | -17.67% | |||
| Year to Date Total Return | -24.92% | |||
| 1-Year Total Return | -17.94% | |||
| 2-Year Total Return | -79.08% | |||
| 3-Year Total Return | -87.65% | |||
| 5-Year Total Return | -95.37% | |||
| 52-Week High % Change | -73.07% | |||
| 52-Week Low % Change | 100.79% | |||
| Price | CYCN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $9.47 | |||
| 52-Week Low Price | $1.27 | |||
| 52-Week Low Price (Date) | Nov 22, 2024 | |||
| 52-Week High Price (Date) | Dec 04, 2024 | |||
| Valuation | CYCN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 6.47M | |||
| Enterprise Value | 3.24M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.23 | |||
| Earnings Per Share Growth | -53.05% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 3.24 | |||
| Price/Book (Q) | 0.73 | |||
| Enterprise Value/Revenue (TTM) | 1.62 | |||
| Price | $2.47 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -0.89 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | CYCN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 2.54M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CYCN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 857 327 8778 | |||
| Address | 245 First Street, Riverview II Cambridge, MA 02142 | |||
| Website | www.cyclerion.com | |||
| Country | United States | |||
| Year Founded | 2018 | |||
| Profitability | CYCN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -181.40% | |||
| Profit Margin | -152.85% | |||
| Management Effectiveness | CYCN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -19.76% | |||
| Return on Equity | -- | |||
| Income Statement | CYCN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 2.00M | |||
| Total Revenue (TTM) | 2.00M | |||
| Revenue Per Share | $0.79 | |||
| Gross Profit (TTM) | 1.85M | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -3.63M | |||
| Net Income (TTM) | -3.06M | |||
| Net Income Avl. to Common (TTM) | -3.06M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 131.29% | |||
| EPS Diluted (TTM) | -1.23 | |||
| EPS Diluted Growth (Q YOY) | 129.84% | |||
| Balance Sheet | CYCN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 3.23M | |||
| Cash Per Share (Q) | $1.27 | |||
| Total Current Assets (Q) | 4.23M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 8.85M | |||
| Current Ratio (Q) | 5.828 | |||
| Book Value Per Share (Q) | $3.49 | |||
| Total Assets (Q) | 9.58M | |||
| Total Current Liabilities (Q) | 725.00K | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 725.00K | |||
| Total Common Equity (Q) | 8.85M | |||
| Cash Flow | CYCN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | -- | |||
| Net Change in Cash (TTM) | -4.34M | |||
| Levered Free Cash Flow (TTM) | -3.54M | |||
| Cash from Operations (TTM) | -4.33M | |||
